Table 1. Baseline demographics and laboratory data of patients who received ritonavir-boosted darunavir- or ritonavir-boosted atazanavir-containing antiretroviral therapy.
| DRV/r (n=540) | ATV/r (n=517) | Pa | |
|---|---|---|---|
| Age, years* | 39 (33-46) | 36 (31-44) | 0.019 |
| Male sex | 498 (92.2) | 480 (92.8) | 0.727 |
| Race (East Asian origin) | 494 (91.5) | 494 (95.6) | 0.009 |
| Body weight, kg* | 62.1 (55.8-70) | 64.0 (57.6-72) | 0.074 |
| body mass index, kg/m2* | 21.7 (19.8-24.1) | 22.4 (20.4-24.6) | 0.014 |
| CD4 cell count, cells/μL* | 251 (90-399) | 260 (190-383) | 0.038 |
| HIV load, log10 copies/mL* | 4.27 (1.70-5.17) | 3.94 (1.70-4.66) | 0.002 |
| Treatment naïve | 309 (57.2) | 280 (54.2) | 0.322 |
| Tenofovir use | 342 (63.3) | 196 (37.9) | <0.001 |
| eGFR, mL/min/1.73 m2* | 116 (102-131) | 115 (103-130) | 0.842 |
| Serum uric acid, mg/dL* | 5.7 (4.7-6.5) | 5.9 (5.1-6.7) | 0.007 |
| HBV or HCV coinfection | 78 (14.4) | 64 (12.4) | 0.367 |
| Past history of nephrolithiasis | 22 (4.1) | 39 (7.5) | 0.017 |
| Previous exposure to IDV | 25 (4.6) | 41 (7.9) | 0.030 |
Data are number (%) of patients or * median (interquartile range).
DRV/r, ritonavir-boosted darunavir; ATV/r, ritonavir-boosted atazanavir; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus, HCV, hepatitis C virus, HIV, human immunodeficiency virus; IDV, indinavir.
a
The χ2 test or Fisher exact test was used for categorical data, and the Student t test was used for continuous variables.